1028 related articles for article (PubMed ID: 10856094)
21. Docetaxel: new indication. First-line treatment of non small-cell lung cancer: no advance.
Prescrire Int; 2005 Feb; 14(75):16-8. PubMed ID: 15751170
[TBL] [Abstract][Full Text] [Related]
22. Combination docetaxel/vinorelbine for metastatic breast cancer and non-small-cell lung cancer.
Aapro MS
Oncology (Williston Park); 1997 Aug; 11(8 Suppl 8):46-9. PubMed ID: 9364543
[TBL] [Abstract][Full Text] [Related]
23. Docetaxel (Taxotere) shows survival and quality-of-life benefits in the second-line treatment of non-small cell lung cancer: a review of two phase III trials.
Shepherd FA; Fossella FV; Lynch T; Armand JP; Rigas JR; Kris MG
Semin Oncol; 2001 Feb; 28(1 Suppl 2):4-9. PubMed ID: 11284623
[TBL] [Abstract][Full Text] [Related]
24. Ifosfamide-based combination chemotherapy in advanced non-small cell lung cancer: two phase I studies.
Hoffman PC; Masters GA; Drinkard LC; Krauss SA; Samuels BL; Golomb HM; Vokes EE
Semin Oncol; 1996 Jun; 23(3 Suppl 6):11-5. PubMed ID: 8677441
[TBL] [Abstract][Full Text] [Related]
25. Taxanes as first-line therapy for advanced non-small cell lung cancer: a systematic review and practice guideline.
Chu Q; Vincent M; Logan D; Mackay JA; Evans WK;
Lung Cancer; 2005 Dec; 50(3):355-74. PubMed ID: 16139391
[TBL] [Abstract][Full Text] [Related]
26. Prospective randomised phase II study of docetaxel versus paclitaxel administered weekly in patients with non-small-cell lung cancer previously treated with platinum-based chemotherapy.
Esteban E; González de Sande L; Fernández Y; Corral N; Fra J; Muñiz I; Vieitez JM; Palacio I; Fernández JL; Estrada E; Lacave AJ;
Ann Oncol; 2003 Nov; 14(11):1640-7. PubMed ID: 14581272
[TBL] [Abstract][Full Text] [Related]
27. The current status of docetaxel for advanced non-small cell lung cancer.
Green MR
Anticancer Drugs; 2001 Feb; 12 Suppl 1():S11-6. PubMed ID: 11340898
[TBL] [Abstract][Full Text] [Related]
28. Docetaxel in second-line treatment of non-small-cell lung cancer.
Fossella FV
Clin Lung Cancer; 2002 May; 3 Suppl 2():S23-8. PubMed ID: 14720344
[TBL] [Abstract][Full Text] [Related]
29. Docetaxel (Taxotere) in the treatment of non-small cell lung cancer (NSCLC)--is there a role for a new chemotherapy programme?
Armand JP
Gan To Kagaku Ryoho; 2000 May; 27 Suppl 2():223-30. PubMed ID: 10895158
[TBL] [Abstract][Full Text] [Related]
30. A randomized trial of different docetaxel schedules in non-small cell lung cancer patients who failed previous platinum-based chemotherapy.
Chen YM; Shih JF; Perng RP; Tsai CM; Whang-Peng J
Chest; 2006 Apr; 129(4):1031-8. PubMed ID: 16608954
[TBL] [Abstract][Full Text] [Related]
31. Docetaxel (Taxotere) and vinorelbine in the treatment of non-small cell lung cancer.
Georgoulias V; Kourousis C; Androulakis N; Kakolyris S; Papadakis E; Bouros D; Apostolopoulou F; Georgopoulou T; Agelidou M; Souglakos J; Halkiadakis G; Hatzidaki D
Semin Oncol; 1997 Aug; 24(4 Suppl 14):S14-9-S14-14. PubMed ID: 9335517
[TBL] [Abstract][Full Text] [Related]
32. Docetaxel (taxotere) in the treatment of non-small cell lung cancer.
Georgoulias V
Curr Med Chem; 2002 Apr; 9(8):869-77. PubMed ID: 11966449
[TBL] [Abstract][Full Text] [Related]
33. Docetaxel vs mitomycin plus vinblastine in anthracycline-resistant metastatic breast cancer.
Nabholtz JM; Thuerlimann B; Bezwoda WR; Melnychuk D; Deschênes L; Douma J; Vandenberg TA; Rapoport B; Rosso R; Trillet-Lenoir V; Drbal J; Aapro MS; Alaki M; Murawsky M; Riva A
Oncology (Williston Park); 1997 Aug; 11(8 Suppl 8):25-30. PubMed ID: 9364538
[TBL] [Abstract][Full Text] [Related]
34. Docetaxel in combination with platinums in patients with advanced non-small-cell lung cancer.
Belani CP
Oncology (Williston Park); 1997 Aug; 11(8 Suppl 8):42-5. PubMed ID: 9364542
[TBL] [Abstract][Full Text] [Related]
35. Docetaxel (Taxotere) as a single agent and in combination chemotherapy for the treatment of patients with advanced non-small cell lung cancer.
Miller VA; Kris MG
Semin Oncol; 2000 Apr; 27(2 Suppl 3):3-10. PubMed ID: 10810932
[TBL] [Abstract][Full Text] [Related]
36. Second line chemotherapy for NSCLC: establishing a gold standard.
Fossella FV; Lynch T; Shepherd FA
Lung Cancer; 2002 Dec; 38 Suppl 4():5-12. PubMed ID: 12480189
[TBL] [Abstract][Full Text] [Related]
37. Weekly vinorelbine and docetaxel as second-line chemotherapy for pretreated non-small cell lung cancer patients: a phase I-II trial.
Nelli F; Naso G; De Pasquale Ceratti A; Saltarelli R; Dauria G; Lugini A; Ferraldeschi R; Picone V; Moscetti L; Cortesi E
J Chemother; 2004 Aug; 16(4):392-9. PubMed ID: 15332716
[TBL] [Abstract][Full Text] [Related]
38. Aflibercept and Docetaxel versus Docetaxel alone after platinum failure in patients with advanced or metastatic non-small-cell lung cancer: a randomized, controlled phase III trial.
Ramlau R; Gorbunova V; Ciuleanu TE; Novello S; Ozguroglu M; Goksel T; Baldotto C; Bennouna J; Shepherd FA; Le-Guennec S; Rey A; Miller V; Thatcher N; Scagliotti G
J Clin Oncol; 2012 Oct; 30(29):3640-7. PubMed ID: 22965962
[TBL] [Abstract][Full Text] [Related]
39. Single agents in the second-line treatment of non-small cell lung cancer.
Belani CP
Semin Oncol; 1998 Jun; 25(3 Suppl 8):10-4. PubMed ID: 9704670
[TBL] [Abstract][Full Text] [Related]
40. Phase I trial of docetaxel and vinorelbine in patients with advanced nonsmall cell lung carcinoma.
Miller VA; Ng KK; Krug LM; Perez W; Pizzo B; Heelan RT; Kris MG
Cancer; 2000 Mar; 88(5):1045-50. PubMed ID: 10699893
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
